JAYKUMAR MARADIA: Open Payments
NPI 1386254134 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 62 payments from 13 companies in 2025. Trend: 2023 $1,441 · 2024 $1,391 · 2025 $1,719
Food & beverage: $1,561Education: $157
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $449 |
| Janssen Pharmaceuticals, Inc | 9 | $325 |
| Neurocrine BioSciences, Inc. | 4 | $202 |
| Otsuka America Pharmaceutical, Inc. | 9 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $153 |
| ABBVIE INC. | 6 | $111 |
| Alkermes, Inc. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: AUSTEDO XR, INGREZZA, SPRAVATO, CAPLYTA, UZEDY, INVEGA SUSTENNA, VRAYLAR, ARISTADA.
Industry payments across CA — which companies pay providers there.
